Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
Related Articles
New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers
A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.
IMMagine-1: Preliminary phase II results of anitocabtagene autoleucel in patients with triple-class exposed RRMM
We summarize key preliminary results from the phase II IMMagine-1 study investigating the efficacy and safety of the BCMA-directed CAR T-cell therapy anitocabtagene autoleucel in…
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets
Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a…
ALLG trial: Ibrutinib plus R-mini-CHOP in older patients with newly diagnosed DLBCL
We summarize key results from the phase II ALLG study of ibrutinib + R-mini-CHOP in older patients with newly diagnosed DLBCL.
Insights into mRNA expression in ADC targets in metastatic breast cancer
Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, discusses findings from the UPTIDER trial (NCT04531696), which analyzed the mRNA expression of 72 antibody-drug conjugate (ADC) targets…
Advances in precision medicine for breast cancer in 2025
Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, provides an overview of recent advancements in precision medicine for breast cancer, emphasizing the…
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL
On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Trump orders US to leave World Health Organization
Trump has long been critical of how the Geneva-based institution handled the Covid-19 pandemic.
Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.